Summary: Anthropic, PBC launched the roadshow for its proposed initial public offering on November 10, 2026, planning to list its Class A common stock on the Nasdaq Global Select Market under the symbol “ANT.” The deal puts 825 million shares into the market at an expected price of $70.00 to $78.00 per share. For anyone building on Anthropic’s models, this is the moment the lab’s funding story shifts from private rounds to quarterly public scrutiny — and it’s worth understanding exactly what is and isn’t locked in yet.
The mechanics of the offering
The proposed offering consists of 825,000,000 shares of Class A common stock, but not all of that money flows to the company. Anthropic itself is offering 801,351,354 shares, while 23,648,646 shares come from certain existing stockholders. Per the announcement, Anthropic will not receive any proceeds from those selling stockholders’ shares — that’s liquidity for insiders, not capital for the business.
On top of the base deal, Anthropic expects to grant the underwriters a 30-day option to purchase up to an additional 123,750,000 shares. That’s a standard overallotment mechanism: if demand runs hot, underwriters can expand the offering by roughly 15% within a month of pricing.
Some quick arithmetic on what the company side could raise — this is my calculation, not a figure from Anthropic’s announcement. At the $70.00 to $78.00 range, the 801,351,354 primary shares imply roughly $56 billion to $62.5 billion in gross proceeds to the company before fees, and up to about $72 billion if the full overallotment option is exercised at the top of the range. Gross, not net — underwriting fees and allocation details aren’t in the announcement.
Who’s running the deal, and how shares get distributed
The offering will be made only by means of a prospectus. Preliminary prospectus copies are available from Goldman Sachs & Co. LLC or Morgan Stanley & Co. LLC, at the addresses and contact details listed in Anthropic’s announcement. Those two names tell you the scale of the bookrunners involved; the announcement doesn’t list the full underwriting syndicate, so I can’t tell you who else is on it.
If you want to actually read the deal terms, the preliminary prospectus is the document to request — not the press release. The prospectus will carry the risk factors, use-of-proceeds language, and share-class structure that a short announcement can’t cover.
What is not settled yet
This is the part worth internalizing before reacting to headlines. A registration statement relating to these securities has been filed with the U.S. Securities and Exchange Commission but has not yet become effective. Until it does, these securities may not be sold, nor may offers to buy be accepted. Today’s announcement explicitly does not constitute an offer to sell or a solicitation of an offer to buy.
What the announcement leaves open: the final price (the $70–$78 range is expected, not fixed), the actual first trading date, whether the offering completes at all, and any detail on financials, valuation, or use of proceeds. The announcement is silent on all of those. If you see coverage quoting a market cap for “ANT,” check whether it’s built on the proposed range or on something sourced elsewhere — the announcement supports only the range itself.
There’s also a structural detail builders sometimes miss: this is a PBC — a public benefit corporation — going public. The announcement doesn’t describe how its governance or charter terms interact with public-market obligations, so any claim about how that balance will hold up under shareholder pressure is speculation, not sourcing.
Why builders should pay attention
When I wrote about Anthropic’s S-1 filing, the ticker “ANT” on Nasdaq was still a paperwork event. A roadshow is different: it means management is actively pitching institutions, the price range is public, and listing is close enough to schedule. Two practical consequences follow.
First, information cadence changes. Once effective, a public Anthropic reports earnings on a fixed schedule, discloses capital spending and revenue in standardized filings, and answers to market reactions in a way a private lab never did. If you’re making platform decisions — how much of your product sits on Claude versus alternatives — those filings become primary-source material you can actually cite, replacing the rumor-driven run-rate coverage that dominates coverage of private AI companies.
Second, capital dynamics shift. My earlier piece on Anthropic’s compute partnership covered a $30B run rate funded through private rounds and multi-gigawatt deals. Public equity is a different funding instrument with different constraints: it’s cheaper at scale but repriced daily. Whether that makes Anthropic a more stable long-term platform partner or a more reactive one is genuinely unknown from this announcement — the documents don’t say how proceeds will be deployed.
What to do next
If this affects your roadmap, do three concrete things. Request or download the preliminary prospectus from Goldman Sachs or Morgan Stanley and read the use-of-proceeds and risk-factor sections directly. Check the SEC’s EDGAR system for the registration statement’s effective date before treating “ANT” as tradeable or the price as final. And once Anthropic is public, set a calendar reminder for its first earnings filing — that will be the first standardized, audited look at the unit economics behind the models you ship on.
Until the registration statement goes effective, though, everything here is a proposal. The range, the share count, and the ticker are on the table; the deal itself isn’t done.
Earlier in this series: Anthropic files S-1: ANT on Nasdaq changes the calculus.